NCT03812042

Brief Summary

Aim is to undertake a screening study that identifies undiagnosed patients with LSDs and determine the prevalence of these diseases with special focus on underrepresented minority groups.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 17, 2016

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

January 18, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 22, 2019

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

January 22, 2019

Status Verified

January 1, 2019

Enrollment Period

3.7 years

First QC Date

January 18, 2019

Last Update Submit

January 18, 2019

Conditions

Keywords

Gaucher diseaseFabry diseasePompe diseaseGangliosidoses

Outcome Measures

Primary Outcomes (2)

  • Enzyme activity analysis to identify subjects with Lysosomal storage disorders

    To identify patients with LSDs using enzymatic activity specific to individual lysosomal storage disorders using left-over blood of blood samples collected as part of standard clinical care.

    5 years

  • Genotypic analysis of subjects with abnormal enzyme activity

    Samples from subjects with abnormally low enzyme activity will be used for targeted sequencing analysis to diagnose any pathologic mutations.

    5 years

Study Arms (1)

Screen population

The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.

Diagnostic Test: Enzyme assay and molecular sequencing

Interventions

Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples

Screen population

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will comprise of patients of healthcare institutions in the Washington, D.C. and Richmond, Virginia areas including but not limited to hospitals, clinics, and doctor's offices.

You may qualify if:

  • Subject is greater than or equal to 1 day of age and less than or equal to 100 years of age
  • Subject is managed by a physician in the Washington, D.C and Richmond, VA metro area
  • Subject is getting blood work as part of standard clinical care and there is at least 60 uL blood remained in a tube after all clinical tests were run

You may not qualify if:

  • Absolute contraindication for blood drawing
  • Subject cannot be traced back by the referring physician upon a positive screening result

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

LDRTC

Fairfax, Virginia, 22030, United States

Location

Related Links

MeSH Terms

Conditions

Lysosomal Storage DiseasesGaucher DiseaseFabry DiseaseGlycogen Storage Disease Type IIGangliosidoses

Condition Hierarchy (Ancestors)

Metabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMetabolic DiseasesNutritional and Metabolic DiseasesSphingolipidosesLysosomal Storage Diseases, Nervous SystemBrain Diseases, Metabolic, InbornBrain Diseases, MetabolicBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesLipidosesLipid Metabolism, Inborn ErrorsLipid Metabolism DisordersCerebral Small Vessel DiseasesCerebrovascular DisordersVascular DiseasesCardiovascular DiseasesGenetic Diseases, X-LinkedGlycogen Storage DiseaseCarbohydrate Metabolism, Inborn Errors

Study Officials

  • Renuka Limgala, PhD

    LDRTC

    PRINCIPAL INVESTIGATOR
  • Margarita M Ivanova, PhD

    LDRTC

    PRINCIPAL INVESTIGATOR
  • Ozlem Goker-Alpan, MD

    LDRTC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 18, 2019

First Posted

January 22, 2019

Study Start

March 17, 2016

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

January 22, 2019

Record last verified: 2019-01

Locations